Filing Details
- Accession Number:
- 0001179110-20-008996
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-13 16:58:26
- Reporting Period:
- 2020-08-11
- Accepted Time:
- 2020-08-13 16:58:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1235010 | Momenta Pharmaceuticals Inc | MNTA | Biological Products, (No Disgnostic Substances) (2836) | 043561634 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1755174 | Ann Jo Beltramello | C/O Momenta Pharmaceuticals, Inc. 301 Binney St, Cambridge MA 02142 | Chief Hr And Inf. Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Commonstock | Acquisiton | 2020-08-11 | 6,250 | $12.76 | 64,080 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-08-11 | 6,250 | $28.03 | 57,830 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-08-12 | 673 | $27.88 | 57,157 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-08-11 | 6,250 | $0.00 | 6,250 | $12.76 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
44,553 | 2020-08-11 | 2029-02-11 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades at prices ranging from $27.95 to $28.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.